Cited 4 times in
Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.contributor.author | 김송이 | - |
dc.contributor.author | 김영삼 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 이상훈 | - |
dc.contributor.author | 장준 | - |
dc.contributor.author | 정지예 | - |
dc.date.accessioned | 2021-09-29T00:46:44Z | - |
dc.date.available | 2021-09-29T00:46:44Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184032 | - |
dc.description.abstract | Background: Pirfenidone is an anti-fibrotic agent shown to slow the progression of idiopathic pulmonary fibrosis (IPF). However, its effectiveness in association with serological autoimmune features in IPF remains unclear. Methods: We retrospectively reviewed the medical records of patients with IPF treated at a tertiary care hospital in South Korea. The autoantibody status was defined as positive if we detected autoantibodies meeting the serological domain criteria for interstitial pneumonia with autoimmune features or anti-neutrophil cytoplasmic antibodies. Results: We included 142 patients with IPF treated with pirfenidone for over six months (93 were autoantibody-positive and 49 were autoantibody-negative). The mean age was 69.5 ± 7.3 years, and 77.5% of the patients were male. The adjusted mean changes over one year were - 34.4 and - 112.2 mL (p = 0.168) in forced vital capacity (FVC), and - 0.53 and - 0.72 mL/mmHg/min (p = 0.356) in the lungs diffusion capacity for carbon monoxide (DLCO) in the autoantibody-negative and autoantibody-positive groups, respectively. Conclusions: Reductions in FVC and DLCO were similar in autoantibody-positive and autoantibody-negative patients with IPF treated with pirfenidone. Pirfenidone is effective in attenuating the progression of IPF, irrespective of the autoantibody status. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC PULMONARY MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Myung Jin Song | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Ji Ye Jung | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.contributor.googleauthor | Moo Suk Park | - |
dc.contributor.googleauthor | Young Sam Kim | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Song Yee Kim | - |
dc.identifier.doi | 10.1186/s12890-021-01516-4 | - |
dc.contributor.localId | A00057 | - |
dc.contributor.localId | A00626 | - |
dc.contributor.localId | A00707 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A02836 | - |
dc.contributor.localId | A03472 | - |
dc.contributor.localId | A03735 | - |
dc.relation.journalcode | J00375 | - |
dc.identifier.eissn | 1471-2466 | - |
dc.identifier.pmid | 33941141 | - |
dc.subject.keyword | Autoantibodies | - |
dc.subject.keyword | Idiopathic pulmonary fibrosis | - |
dc.subject.keyword | Pirfenidone | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | 강영애 | - |
dc.contributor.affiliatedAuthor | 김송이 | - |
dc.contributor.affiliatedAuthor | 김영삼 | - |
dc.contributor.affiliatedAuthor | 박무석 | - |
dc.contributor.affiliatedAuthor | 이상훈 | - |
dc.contributor.affiliatedAuthor | 장준 | - |
dc.contributor.affiliatedAuthor | 정지예 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 145 | - |
dc.identifier.bibliographicCitation | BMC PULMONARY MEDICINE, Vol.21(1) : 145, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.